The Guangdong Provincial People’s Hospital (GDPH) and regional Asia-Pacific clinical research organization (CRO) George Clinical have inked a memorandum of understanding (MOU) outlying a collaborative business framework in the area of clinical research in China. The duo seek to pursue training and education in clinical trial services, scientific networking and involvement in trial-related activities, provision of medical monitoring, in-depth feasibility services and investigator networks. China’s clinical research sector is now white hot, and George Clinical seeks to tap in and extend its influence there.
The CRO and Research Center Collaboration: Raising the GcP Bar in China
As China’s clinical research rapidly expands, the level of education, training and “vocational certainty” must evolve. TrialSite News has reported on a number of similar initiatives in China, such as the Eli Lilly and Parexel effort.
The pair here will seek to address several key areas of clinical research operations, including Guangdong Provincial People’s Hospital’s personnel training including investigators, study coordinators, and those relatively new to global clinical trials to build expertise in Good Clinical Practices in areas such as basic GCP training, workshops, and inspection preparation. Consulting in setting up clinical trials unit at Guangdong Provincial People’s Hospital will seek to bring world-class competency using the collaboration methods established in previous trial work.
Guangdong Provincial People’s Hospital Seeks to become a Hub of Investigator Networks
Guangdong Provincial People’s Hospital will become a hub for investigator networks in China as well as George Clinical trials in China and the Asia-Pacific Region. The hospital will now be included in the feasibility of new studies in selected therapeutic areas, such as nephrology, oncology and cardiovascular diseases. The partnership will benefit from the recommendations of key opinion leaders from GDPH for trial-related activities, such as data safety monitoring boards (DSMB), steering committees and more.
A Big Deal for George Clinical—They now have a Value-Added Network to Mobilize for Sponsors
With this deal, now George Clinical can tap into Guangdong Provincial People’s Hospital clinicians and their networks for the provision of medical monitoring services (CRA services) in China under the standard operating procedures (SOPs) of George Clinical. This also comprises the referral of Guangdong Provincial People’s Hospital staff for the provision of bio-statistical and data management services under the training and oversight of George Clinical. Moving forward, if George Clinical plays its cards correctly out in the market, they could have tremendous advantage with the ability to leverage a multitude of investigators and staff for clinical trials services all under the George GcP umbrella. As George Clinical’s COO James Cheong noted, “This relationship will be a key part of our expanding presence in China.”
Part of Strengthening China’s Clinical Investigator Capacity and Capability for Drug Development
Xueqing Yu, President of Guangdong Provincial People’s Hospital, noted, “At the beginning of 2019, the CPC Central Committee and the State Council issued the Development Planning Outline of the Greater Bay Area, which identified academic cooperation and scientific research as the bridge to in-depth cooperation for Guangdong, Hong Kong and Macau in the field of medical health. It is hoped with our bilateral cooperation as a starting point, we can focus on the development goal of the regional integration in the Greater Bay Area, promote in-depth cooperation in the medical and health field, establish a platform for communication and collaboration and model.”
George Clinical Background
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With 20 years of experience and more than 300 people managing 38 geographical locations throughout the USA, Asia-Pacific region and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.
Guangdong Provincial People’s Hospital
It is a large hospital founded in 1946 and located in Yuexiu District, Guangzhou, Guangdong, China. It is conveniently located at the juncture of Zhongshan Er Rd. and Dongchuan Rd. The hospital occupies a total area of 49,000m2, and the architectural area adds up to 220,000m2. Now there are 3,184 working staffs, among which there are 2,694 medical staffs. The hospital has 2,052 beds. The annual number of discharge is over 50,000 and the number of out-patients of its five out-patient departments amounts to 2,680,000. The hospital consists of five institutes, namely Guangdong Provincial Cardiovascular Institute, Guangdong Provincial Gerontology Institute, Guangdong Provincial Mental Health Institute, Guangdong Provincial Lung Cancer Institute and Guangdong Village Ophthalmology Institute. Moreover, the hospital has strong capacity in medical treatment, teaching and research and is composed of the following medical organizations, namely Guangdong Weilun PET Center, Guangdong Weilun Endoscope Center, Guangdong Clinical Examination Center, Guangdong Center for Village Ophthalmopathy Prevention and Control, and Guangdong Marrow Bank.
Call to Action: Interested in learning more? Contact George Clinical for business with them. We are not sure if this is an exclusive deal. Perhaps not? Xueqing Yu leads Guangdong Provincial People’s Hospital.